The Promise of MDMA in the Future Treatment of Severe Post-Traumatic Stress Disorder
DOI:
https://doi.org/10.47611/jsrhs.v13i2.6443Keywords:
PTSD, MDMA, PsychedelicsAbstract
Post-traumatic stress disorder (PTSD) is an often debilitating condition caused by a person’s exposure to traumatic events. Symptoms of PTSD include intrusive thoughts, suicidal ideation, and highly negative and distressing emotional states. Current treatments for PTSD such as cognitive behavioral therapy, EMDR, and SSRIs and SNRIs are ineffective for a large chunk of patients who seek out treatment. A majority of patients with PTSD do not respond to talking therapy, and the remission rate for patients on SSRIs and SNRIs is low. The ineffectiveness of recommended treatments has led to experimentation with drugs like MDMA. MDMA increases levels of chemicals in the brain that induce happy and calm states. This drug also decreases fear states in patients, allowing them to more comfortably discuss traumatic events without the possible side effects of extreme emotional numbness or high levels of anxiety. Research conducted in the last decade on MDMA in addition to psychotherapy in a clinical setting has yielded impressive results. A majority of patients in all three conducted trials experienced a long-term reduction in PTSD symptoms. MDMA in a clinical setting was also proven to be safe, with no serious drug-related side effects on patients. With such high rates of symptom reduction, these studies provide hope for the future of effective and safe PTSD treatment.
Downloads
References or Bibliography
Baier, A. D. (2013). Low doses of psychedelic drug erases conditioned fear in mice. USF Health. https://hscweb3.hsc.usf.edu/blog/2013/07/15/low-doses-of-psychedelic-drug-erases-conditioned-fear-in-mice/.
Belouin, S. J., & Henningfield, J. E. (2018). Psychedelics: Where we are now, why we got here, what we must do. Neuropharmacology (Vol. 142, pp. 7–19). Elsevier BV. https://doi.org/10.1016/j.neuropharm.2018.02.018.
Berger, W., Mendlowicz, M. V., Marques-Portella, C., Kinrys, G., Fontenelle, L. F., Marmar, C. R., & Figueira, I. (2009). Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review. Progress in neuro-psychopharmacology & biological psychiatry, 33(2), 169–180. https://doi.org/10.1016/j.pnpbp.2008.12.004.
Bouso, J. C., Doblin, R., Farré, M., Alcázar, M. A., & Gómez-Jarabo, G. (2008). MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. Journal of psychoactive drugs, 40(3), 225–236. https://doi.org/10.1080/02791072.2008.10400637.
Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018). Psychedelics and the essential importance of context. Journal of Psychopharmacology (Vol. 32, Issue 7, pp. 725–731). SAGE Publications. https://doi.org/10.1177/0269881118754710.
Cautions - Selective serotonin reuptake inhibitors (SSRIs). (n.d.). https://www.nhs.uk/mental-health/talking-therapies-medicine-treatments/medicines-and-psychiatry/ssri-antidepressants/considerations/.
Feduccia, A. A., & Mithoefer, M. C. (2018). MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? Progress in Neuro-Psychopharmacology and Biological Psychiatry (Vol. 84, pp. 221–228). Elsevier BV. https://doi.org/10.1016/j.pnpbp.2018.03.003.
Goldman, B. (2019). Rave new world: Scientists Pry Apart Party Drug’s therapeutic, addictive qualities. Stanford Medicine News Center. https://med.stanford.edu/news/all-news/2019/12/rave-new-world-scientists-pry-apart-party-drugs-therapeutic.html.
Is MDMA addictive? (2021). https://nida.nih.gov/publications/research-reports/mdma-ecstasy-abuse/mdma.
Jerome, L., Feduccia, A. A., Wang, J. B., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Mithoefer, M. C., & Doblin, R. (2020). Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology, 237(8), 2485–2497. https://doi.org/10.1007/s00213-020-05548-2.
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G., M., Garas, W., Paleos, C., Gorman, I., Nicholas, C., Mithoefer, M., Carlin, S., Poulter, B., Mithoefer, A., Quevedo, S., Wells, G., Klaire, S. S., van der Kolk, B., … Doblin, R. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine (Vol. 27, Issue 6, pp. 1025–1033). Springer Science and Business Media LLC. https://doi.org/10.1038/s41591-021-01336-3.
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2010). The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of Psychopharmacology (Vol. 25, Issue 4, pp. 439–452). SAGE Publications. https://doi.org/10.1177/0269881110378371.
Nutt D. (2019). Psychedelic drugs-a new era in psychiatry?. Dialogues in clinical neuroscience, 21(2), 139–147. https://doi.org/10.31887/DCNS.2019.21.2/dnutt.
Oehen, P., Traber, R., Widmer, V., & Schnyder, U. (2012). A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). Journal of Psychopharmacology (Vol. 27, Issue 1, pp. 40–52). SAGE Publications. https://doi.org/10.1177/0269881112464827.
Schrader, C., & Ross, A. (2021). A Review of PTSD and Current Treatment Strategies. Missouri medicine, 118(6), 546–551. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672952/
Weathers, F.W., Blake, D.D., Schnurr, P.P., Kaloupek, D.G., Marx, B.P., & Keane, T.M. (2013). The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). https://www.ptsd.va.gov.
Young, M. B., Andero, R., Ressler, K. J., & Howell, L. L. (2015). 3,4-Methylenedioxymethamphetamine facilitates fear extinction learning. Translational psychiatry, 5(9), Article e634. https://doi.org/10.1038/tp.2015.138.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Mia Panin; Jason Abercrombie
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
